CA3219155A1 - Nicotinamide ripk1 inhibitors - Google Patents
Nicotinamide ripk1 inhibitors Download PDFInfo
- Publication number
- CA3219155A1 CA3219155A1 CA3219155A CA3219155A CA3219155A1 CA 3219155 A1 CA3219155 A1 CA 3219155A1 CA 3219155 A CA3219155 A CA 3219155A CA 3219155 A CA3219155 A CA 3219155A CA 3219155 A1 CA3219155 A1 CA 3219155A1
- Authority
- CA
- Canada
- Prior art keywords
- hydrogen
- mmol
- compound
- unsubstituted
- substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pyridine Compounds (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163231590P | 2021-08-10 | 2021-08-10 | |
| US63/231,590 | 2021-08-10 | ||
| PCT/US2022/039689 WO2023018643A1 (en) | 2021-08-10 | 2022-08-08 | Nicotinamide ripk1 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3219155A1 true CA3219155A1 (en) | 2023-02-16 |
Family
ID=83439074
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3219155A Pending CA3219155A1 (en) | 2021-08-10 | 2022-08-08 | Nicotinamide ripk1 inhibitors |
Country Status (15)
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202321211A (zh) | 2021-08-10 | 2023-06-01 | 美商艾伯維有限公司 | 菸鹼醯胺ripk1抑制劑 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997005131A1 (en) | 1995-08-02 | 1997-02-13 | J. Uriach & Cia. S.A. | New carboxamides with antifungal activity |
| US6218387B1 (en) | 1996-12-20 | 2001-04-17 | Hoechst Aktiengesellschaft | Vitronectin receptor anatagonists, their preparation and their use |
| US6723727B1 (en) | 1996-12-20 | 2004-04-20 | Hoechst Aktiengesellschaft | Substituted purine derivatives, processes for their preparation, their use, and compositions comprising them |
| CA2533889A1 (en) | 2003-08-15 | 2005-03-03 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| US7465746B2 (en) | 2003-08-15 | 2008-12-16 | Merck & Co., Inc. | Fluorinated 2,4-diaryl-2,5-dihydropyrrole inhibitors of the mitotic kinesin KSP |
| US7112316B1 (en) | 2005-08-08 | 2006-09-26 | Uop Llc | Process for preparing molecular sieves via continuous addition of nutrients |
| EP1984355A2 (en) | 2006-02-16 | 2008-10-29 | Takeda Pharmaceutical Company Limited | Cyclic amine compound and use thereof for the prophylaxis or treatment of hypertension |
| ATE505454T1 (de) | 2007-09-20 | 2011-04-15 | Amgen Inc | 1-(4-(4-benzylbenzamid)-benzyl)-azetidin-3- carboxylsäurederivate und entsprechende verbindungen als s1p-rezeptor-modulatoren zur behandlung von immunerkrankungen |
| AU2009225869B2 (en) | 2008-03-18 | 2014-01-23 | Merck Sharp & Dohme Llc | Substituted 4-hydroxypyrimidine-5-carboxamides |
| WO2010120935A1 (en) | 2009-04-15 | 2010-10-21 | Abbott Laboratories | Anti-viral compounds |
| WO2011113707A1 (en) | 2010-03-17 | 2011-09-22 | Exxonmobil Chemical Patents Inc. | Plasticiser blends and compositions and articles made therefrom |
| CA2815131C (en) | 2010-10-20 | 2020-06-09 | Gruenenthal Gmbh | Substituted 6-amino-nicotinamides as kcnq2/3 modulators |
| WO2013049255A1 (en) | 2011-09-26 | 2013-04-04 | Vanderbilt University | Substitued 5-(prop-1-yn-1-yl)picolinamide analogs as allosteric modulators of mglur5 receptors |
| TWI648274B (zh) | 2013-02-15 | 2019-01-21 | 英商葛蘭素史克智慧財產發展有限公司 | 作為激酶抑制劑之雜環醯胺類 （二） |
| EA032355B1 (ru) | 2013-12-24 | 2019-05-31 | Онкотартис, Инк. | Бензамидные и никотинамидные соединения и способы их применения |
| KR101555033B1 (ko) | 2014-07-28 | 2015-09-23 | 충남대학교산학협력단 | 신규한 메타논 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 망막 질환의 예방 또는 치료용 약학적 조성물 |
| KR101551313B1 (ko) | 2014-07-28 | 2015-09-09 | 충남대학교산학협력단 | 신규한 인덴 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 망막 질환의 예방 또는 치료용 약학적 조성물 |
| RU2017109122A (ru) | 2014-08-21 | 2018-09-21 | Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед | Способы лечения с использованием гетероциклических амидов в качестве ингибиторов киназы |
| EP3224237B1 (en) | 2014-12-24 | 2024-09-11 | National Institute Of Biological Sciences, Beijing | Necrosis inhibitors |
| UY36680A (es) | 2015-05-19 | 2016-12-30 | Glaxosmithkline Ip Dev Ltd | Amidas heterocíclicas como inhibidores de quinasa |
| RU2716136C2 (ru) | 2015-07-02 | 2020-03-06 | Ф. Хоффманн-Ля Рош Аг | Бициклические лактамы и способы их применения |
| WO2017069279A1 (ja) | 2015-10-23 | 2017-04-27 | 武田薬品工業株式会社 | 複素環化合物 |
| CN108602809B (zh) | 2015-12-04 | 2022-09-30 | 戴纳立制药公司 | 异噁唑烷衍生的受体相互作用蛋白激酶1(ripk 1)的抑制剂 |
| US10961258B2 (en) | 2015-12-21 | 2021-03-30 | Glaxosmithkline Intellectual Property Development Limited | Heterocyclic amides as kinase inhibitors |
| US9815850B2 (en) | 2016-02-05 | 2017-11-14 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| EP3515447A4 (en) | 2016-09-26 | 2020-05-27 | Tufts University | Uridine nucleoside derivatives, compositions and methods of use |
| LT3580220T (lt) | 2017-02-13 | 2021-12-27 | Bristol-Myers Squibb Company | Aminotriazolopiridinai, kaip kinazės inhibitoriai |
| DE102017211104B3 (de) | 2017-06-29 | 2018-10-18 | Bundesdruckerei Gmbh | Verfahren und Vorrichtung zum Verifizieren eines elektrolumineszierenden Sicherheitsmerkmals in einem Wert- oder Sicherheitsdokument unter Ausnutzung von zusätzlicher Lichtstrahlung |
| CN111566103B (zh) * | 2017-10-30 | 2023-06-23 | 百时美施贵宝公司 | 作为激酶抑制剂的氨基咪唑并吡嗪 |
| US11618753B2 (en) * | 2018-01-26 | 2023-04-04 | Bristol-Myers Squibb Company | Aminopyrrolotriazines as kinase inhibitors |
| SI3788044T1 (sl) | 2018-05-03 | 2023-12-29 | Rigel Pharmaceuticals, Inc. | Spojine, ki zavirajo RIP1 in postopki za njihovo izdelavo in uporabo |
| WO2020007234A1 (zh) * | 2018-07-02 | 2020-01-09 | 深圳市塔吉瑞生物医药有限公司 | 用于抑制蛋白激酶活性的炔基(杂)芳环类化合物 |
| WO2020013531A1 (ko) | 2018-07-10 | 2020-01-16 | 보로노이바이오 주식회사 | N-(3-(이미다조[1,2-b]피리다진-3-일에티닐)-4-메틸페닐)-5-페닐-4,5-다이하이드로-1H-피라졸-1-카복사마이드 유도체 및 이를 유효성분으로 포함하는 키나아제 관련 질환 치료용 약학적 조성물 |
| WO2020149553A1 (ko) * | 2019-01-15 | 2020-07-23 | 주식회사 보로노이 | 아릴 또는 헤테로아릴 유도체, 및 이를 유효성분으로 포함하는 키나아제 관련 질환 치료용 약학적 조성물 |
| TW202321211A (zh) | 2021-08-10 | 2023-06-01 | 美商艾伯維有限公司 | 菸鹼醯胺ripk1抑制劑 |
-
2022
- 2022-08-08 TW TW111129732A patent/TW202321211A/zh unknown
- 2022-08-08 WO PCT/US2022/039689 patent/WO2023018643A1/en not_active Ceased
- 2022-08-08 AR ARP220102125A patent/AR126733A1/es not_active Application Discontinuation
- 2022-08-08 CA CA3219155A patent/CA3219155A1/en active Pending
- 2022-08-08 US US17/882,709 patent/US11767310B2/en active Active
- 2022-08-08 KR KR1020237038931A patent/KR102707109B1/ko active Active
- 2022-08-08 IL IL308349A patent/IL308349A/en unknown
- 2022-08-08 BR BR112023025850A patent/BR112023025850A2/pt unknown
- 2022-08-08 EP EP25189687.4A patent/EP4643949A3/en active Pending
- 2022-08-08 EP EP22777032.8A patent/EP4301744A1/en not_active Withdrawn
- 2022-08-08 JP JP2023516136A patent/JP7406672B2/ja active Active
- 2022-08-08 KR KR1020247029687A patent/KR20240135076A/ko active Pending
- 2022-08-08 CN CN202280041334.6A patent/CN117460722A/zh active Pending
- 2022-08-08 MX MX2023014817A patent/MX2023014817A/es unknown
- 2022-08-08 AU AU2022328136A patent/AU2022328136A1/en not_active Abandoned
-
2023
- 2023-11-17 ZA ZA2023/10682A patent/ZA202310682B/en unknown
- 2023-12-11 CO CONC2023/0017151A patent/CO2023017151A2/es unknown
- 2023-12-14 JP JP2023210859A patent/JP2024037892A/ja active Pending
-
2024
- 2024-03-18 US US18/608,389 patent/US20240360099A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2023014817A (es) | 2024-01-12 |
| ZA202310682B (en) | 2024-08-28 |
| CN117460722A (zh) | 2024-01-26 |
| EP4301744A1 (en) | 2024-01-10 |
| EP4643949A2 (en) | 2025-11-05 |
| AR126733A1 (es) | 2023-11-08 |
| TW202321211A (zh) | 2023-06-01 |
| AU2022328136A1 (en) | 2023-11-30 |
| JP2024037892A (ja) | 2024-03-19 |
| KR20230163568A (ko) | 2023-11-30 |
| JP2023549007A (ja) | 2023-11-22 |
| US20230127127A1 (en) | 2023-04-27 |
| IL308349A (en) | 2024-01-01 |
| KR20240135076A (ko) | 2024-09-10 |
| EP4643949A3 (en) | 2026-01-07 |
| US11767310B2 (en) | 2023-09-26 |
| US20240360099A1 (en) | 2024-10-31 |
| WO2023018643A1 (en) | 2023-02-16 |
| JP7406672B2 (ja) | 2023-12-27 |
| BR112023025850A2 (pt) | 2024-03-05 |
| CO2023017151A2 (es) | 2023-12-29 |
| KR102707109B1 (ko) | 2024-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7591500B2 (ja) | ピロロピリミジンｉｔｋ阻害剤 | |
| CN114380801B (zh) | 氨基嘧啶ssao抑制剂及其制备方法 | |
| US11559538B2 (en) | Substituted 1,2-oxaborolan-2-ols as PDE4 inhibitors | |
| KR20250121029A (ko) | 두드러기 치료를 위한 야생형 c-kit 키나제 억제제로서의 n-페닐-피라졸로[1,5-a]피리딘-3-카르복사미드 유도체 | |
| JP2019524716A (ja) | バニン１酵素の阻害薬としての新規のピリミジンカルボキサミド | |
| EP3402789B1 (en) | Isoquinolones as btk inhibitors | |
| CA3142478A1 (en) | Cot modulators and methods of use thereof | |
| KR102707109B1 (ko) | 니코틴아미드 ripk1 억제제 | |
| JP7447098B2 (ja) | アミノピリミジン化合物 | |
| EP4051679A1 (en) | Condensed pyridazine or pyrimidine as btk inhibitors | |
| KR20250174945A (ko) | 케토헥소키나아제 억제를 위한 이치환 피리미딘 화합물 | |
| RU2793936C2 (ru) | Борсодержащие ингибиторы pde4 | |
| WO2025049774A1 (en) | (e)-2-(benzylamino)-n-(3-(methylsulfonyl)allyl)-benzamide derivatives and similar compounds as jak1 inhibitors for the treatment of inflammatory diseases, autoimmune diseases or cancer | |
| KR20250044660A (ko) | N-(2-(3-시아노-2-아자바이사이클로[3.1.0]헥산-2-일)-2-옥소에틸)-퀴놀린-4-카르복스아미드 | |
| HK40121269A (en) | Pyrimidines for degrading bruton's tyrosine kinase | |
| CA3248245A1 (en) | Pyrimidines for degrading bruton's tyrosine kinase | |
| EA050573B1 (ru) | N-(2-(3-циано-2-азабицикло[3.1.0]гексан-2-ил)-2-оксоэтил)хинолин-4-карбоксамиды | |
| KR20230100919A (ko) | 아미노피리미디닐 유도체 | |
| HK40050998A (en) | Boron containing pde4 inhibitors | |
| KR20220054626A (ko) | 피라졸 화합물, 이의 제형, 및 화합물 및/또는 제형을 사용하는 방법 | |
| OA20225A (en) | Baron containing PDE4 inhibitors. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD Year of fee payment: 2 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20240719 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20240719 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20240719 |
|
| P22 | Classification modified |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P22-P110 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CLASSIFICATION MODIFIED Effective date: 20241127 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250709 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250709 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260709 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260709 |